Advancements in personalized medicine and other innovations are transforming the way dosage forms are viewed.

Reshaping Dosage Forms

This study aimed to develop a taste-masked drug resin complex using the ion exchange resin Kyron T-114.

Development of Taste-Masked Oral Dispersible Tablets of Cefpodoxime Proxetil

Novel genetic engineering technologies are transforming the design and manufacture of bispecific antibodies, which are emerging as a promising new class of biologics.

Frontrunners in Bispecific Antibodies

Topic

Articles

The author outlines how to choose carriers and capsule shells according to dosage requirements and intended use. This article is part of a special Drug Delivery issue.

Capsule-in-Capsule Technology

The author reviews advances in technology that may soon allow transdermal delivery of two of the fastest growing drug classes on the pharmaceutical market. This article is part of a special Drug Delivery issue.

Transdermal Delivery of Vaccines and Therapeutic Proteins

Yoen-Ju Son is Visiting Research Scientist at College of Pharmacy, University of Texas at Austin (TX, USA).

Jason McConville is Assistant Professor, Director of InstrUcTex, at College of Pharmacy, University of Texas at Austin (TX, USA)

Although there are no regulatory requirements or established pharmacopoeial techniques for the dissolution testing of inhaled drugs, such testing can potentially open up the opportunity to tailor formulation properties.

Dissolution Testing For Inhaled Drugs

Patricia Van Arnum was executive editor of Pharmaceutical Technology.

Pfizer announced this his week that it had entered into a strategic global agreement for the worldwide commercialization with the Indian biotechnology company Biocon (Bangalore) for biosimilar versions of insulin and insulin analog products (e.g., recombinant human insulin, glargine, aspart, and lispro).

Pfizer Takes Biosimilars Plunge

FDA to Hold Public Hearing on Biosimilars Legislation, And More.

Regulatory Roundup: FDA to Hold Public Hearing on Biosimilars Legislation, And More.

A recently released industry guide outlines a science- and risk-based approach to control the risk of cross-contamination.

Risk Mitigation in High-Potency Manufacturing

Michelle Hoffman, editorial director of Pharmaceutical Technology.

Drugmakers hatch new manufacturing paradigms in the wake of the 2009 H1N1 influenza pandemic.

Vaccine Manufacturing Reborn

Angie Drakulich was editorial director of Pharmaceutical Technology.

A look at MVI's malaria work in developing countries.

Global Healthcare on the Ground: The PATH Malaria Vaccine Initiative

Novartis' Matthew Stober discusses vaccine manufacturing, including egg- and cell-based systems.

Novartis's Influenza Vaccine Program: A conversation with Matthew Stober, global head of technical operations for Novartis

Jill Wechsler is Pharmaceutical Technology's Washington Editor, jillwechsler7@gmail.com.

President Obama and HHS eye innovation and countermeasures to protect public health.